[embedded content] #Lyft #Uber #DoorDash #yahoofinanceMichael Morton, SVB MoffettNathanson Sr. Research Analyst, discusses Outperform calls on Uber and DoorDash.Key Video Takeaways00:18 On Lyft’s business00:30 On Uber & DoorDash’s businesses00:48 On Lyft’s struggle to get drivers00:57 On Lyft’s analyst rating Don’t Miss: Valley of Hype: The culture that built Elizabeth HolmesWATCH HERE: [embedded content] Subscribe to […]

Although market analysts often pound the table on electric vehicles, the harsh reality is that one must exercise discretion with EV stocks. Frankly, most of the upstart brands that you see today probably won’t be with us several years down the line. Here, it’s useful to take a quick history lesson. Back during the early

[embedded content] Subadra Rajappa of Societe General says markets may be “underpricing” the risk of Fed hikes this year. She’s on Bloomberg Surveillance with Lisa Abramowicz.——–Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.comConnect with us on…Twitter: https://twitter.com/businessFacebook: https://www.facebook.com/bloombergbusinessInstagram: https://www.instagram.com/bloombergbusiness/

Many investors understand the benefits of diversifying their portfolios. Diversification across various asset classes is a part of this discussion. Indeed, holding a certain percentage of high-growth stocks in addition to defensive dividend-paying names is a great way to build long-term wealth. There’s currently a very conspicuous shift happening in the market right now. Investors are

[embedded content] #stockstowatch #inflation #YahooFinance #recession #bitcoin #Biden #Stockmarket #coronavirus #memestocks #Fed #YahooFinance #investing #stockmarket #bitcoin #crypto To get the latest market news check out finance.yahoo.com

To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases is impressive. However, many gene editing stocks are making waves, looking to advance toward eradicating